Merck 3Q

Merck

3Q Revenues: $6.1 billion (+12%)

3Q Earnings: $1.5 billion (+62%)

YTD Revenues: $18.0 billion (+8%)

YTD Earnings: $4.9 billion (+24%)

Comments: Singulair sales rose 17% to $1 billion. Diabetes treatment Januvia, launched in October 2006, posted $185 million in 3Q07 sales. Gardasil, the HPV vaccine approved in the U.S. in June 2006, posted worldwide sales of $418 million. Sales of Zetia and Vytorin are not recognized as revenues, but as equity from a joint venture. The cholesterol treatments products reached all-time highs in prescriptions in 3Q07, and posted combined sales of $1.3 billion (+26%), of which Merck recognizes approximately half.